Edition:
India

Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

8.93USD
15 Nov 2019
Change (% chg)

$-0.69 (-7.17%)
Prev Close
$9.62
Open
$9.63
Day's High
$9.79
Day's Low
$8.73
Volume
22,435
Avg. Vol
25,991
52-wk High
$15.49
52-wk Low
$4.11

Latest Key Developments (Source: Significant Developments)

Arcturus Therapeutics Posts Q1 Loss Per Share of $0.68
Monday, 13 May 2019 

May 13 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q1 LOSS PER SHARE $0.68.Q1 EARNINGS PER SHARE ESTIMATE $-0.58 -- REFINITIV IBES DATA.REMAINS ON TRACK TO REDOMICILE FROM AN ISRAELI LIMITED COMPANY TO A DELAWARE CORPORATION.QTRLY COLLABORATION REVENUE WAS $4.4 MILLION VERSUS $2.4 MILLION.Q1 REVENUE VIEW $3.1 MILLION -- REFINITIV IBES DATA.  Full Article

Arcturus Therapeutics Reassumes Full Worldwide Rights To Arct-810, A Clinical Development Candidate For Ornithine Transcarbamylase Deficiency
Monday, 11 Feb 2019 

Feb 11 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS REASSUMES FULL WORLDWIDE RIGHTS TO ARCT-810, A CLINICAL DEVELOPMENT CANDIDATE FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY.ARCTURUS THERAPEUTICS LTD - CUREVAC ELECTED NOT TO CONTINUE ITS OBLIGATIONS FOR PRECLINICAL DEVELOPMENT OF ARCT-810.ARCTURUS THERAPEUTICS LTD - ARCT-810 WAS PREVIOUSLY SUBJECT TO A 50/50 COLLABORATION BETWEEN ARCTURUS AND CUREVAC AG.ARCTURUS THERAPEUTICS LTD - PRECLINICAL DEVELOPMENT PROGRAM FOR ARCT-810 INCLUDING IND ENABLING STUDIES, REMAINS ON TRACK.ARCTURUS THERAPEUTICS LTD - PLANNING TO FILE AN IND FOR ARCT-810 WITH U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2019.  Full Article

Arcturus Therapeutics Q3 Loss Per Share $0.42
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.42.  Full Article

Arcturus Therapeutics Q2 Loss Per Share $0.99
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.99.CASH, CASH EQUIVALENTS, & INVESTMENTS TOTALED $39.8 MILLION AS OF JUNE 30, 2018.APPOINTED ANDREW SASSINE AS INTERIM CHIEF FINANCIAL OFFICER, EFFECTIVE AUGUST 24, 2018.REVENUE OF $2.4 MILLION, COMPARED WITH $3.8 MILLION DURING Q2 OF 2017.  Full Article

Arcturus Says Founder Joseph Payne Reinstated As President And CEO
Thursday, 31 May 2018 

May 31 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS ANNOUNCES MANAGEMENT APPOINTMENTS; COMPANY FOUNDER JOSEPH E. PAYNE REINSTATED AS PRESIDENT AND CEO.ARCTURUS THERAPEUTICS LTD - PAD CHIVUKULA HAS BEEN REINSTATED AS CHIEF SCIENTIFIC OFFICER AND CHIEF OPERATING OFFICER.ARCTURUS THERAPEUTICS LTD - PETER FARRELL HAS BEEN NAMED AS CHAIRMAN OF BOARD OF DIRECTORS OF COMPANY.  Full Article

Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics
Tuesday, 1 May 2018 

April 30 (Reuters) - Arcturus Therapeutics Ltd ::AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING.AMIR EFRATI REPORTS 5.3 PERCENT STAKE IN ARCTURUS THERAPEUTICS AS OF APRIL 27, 2018 - SEC FILING.AMIR EFRATI SAYS INTEND TO REVIEW INVESTMENT IN ARCTURUS THERAPEUTICS ON A CONTINUING BASIS.AMIR EFRATI SAYS PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SHARES, WHEN PURCHASED, WERE UNDERVALUED.  Full Article

Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne
Monday, 23 Apr 2018 

April 23 (Reuters) - Arcturus Therapeutics Ltd ::JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE.JOSEPH PAYNE SAYS OWNS APPROXIMATELY 13.7% OF ISSUED AND OUTSTANDING SHARES OF ARCTURUS THERAPEUTICS.JOSEPH PAYNE SAYS URGES ARCTURUS THERAPEUTICS' BOARD TO SET DATE FOR THE EXTRAORDINARY GENERAL MEETING THAT PAYNE FILED FORMAL REQUEST FOR ON FEB 12.  Full Article

Bradley Thomas Sorenson Reports 5.6 Pct Stake In Arcturus Therapeutics As Of Nov. 16, 2017
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Bradley Thomas Sorenson: :BRADLEY THOMAS SORENSON REPORTS 5.6 PERCENT STAKE IN ARCTURUS THERAPEUTICS LTD AS OF NOVEMBER 16, 2017 - SEC FILING.BRADLEY THOMAS SORENSON - PURCHASED ARCTURUS THERAPEUTICS' SHARES BASED ON BELIEF THAT SUCH SECURITIES, WHEN PURCHASED, WERE "UNDERVALUED".  Full Article

Arcturus Announces Expansion Of Collaboration With Takeda
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Arcturus Therapeutics Ltd ::ARCTURUS THERAPEUTICS ANNOUNCES EXPANSION OF COLLABORATION WITH TAKEDA PHARMACEUTICALS TO DEVELOP RNA-BASED THERAPEUTICS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) AND OTHER GI DISORDERS.ARCTURUS THERAPEUTICS - TAKEDA, CO TO DEVELOP RNA-BASED THERAPEUTICS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS, OTHER GASTROINTESTINAL.ARCTURUS - TO DEVELOP TREATMENT OF NASH AND GI RELATED DISORDERS USING CO'S LUNAR LIPID-MEDIATED DELIVERY SYSTEMS & UNA OLIGOMER CHEMISTRY.  Full Article

Arcturus and Curevac Enter Into Strategic Collaboration To Jointly Novel Messenger RNA Therapeutics
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Arcturus Therapeutics Ltd ::CO, CUREVAC AG ENTER INTO STRATEGIC COLLABORATION TO JOINTLY DISCOVER, DEVELOP,COMMERCIALIZE NOVEL MESSENGER RNA THERAPEUTICS.DEVELOPMENT COSTS WILL BE SHARED BETWEEN COS,WITH PLANS TO CO-COMMERCIALIZE PRODUCTS IN FUTURE UNDER PROFIT SHARING ARRANGEMENT.  Full Article